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Abstract
Background: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor, which plays a central
role in biologic processes under hypoxic conditions, especially concerning tumour angiogenesis.
HIF-1α is the relevant, oxygen-dependent subunit and its overexpression has been associated with
a poor prognosis in a variety of malignant tumours. Therefore, HIF-1α expression in early stage
oral carcinomas was evaluated in relation to established clinico-pathological features in order to
determine its value as a prognostic marker.
Methods: 85 patients with histologically proven surgically treated T1/2 squamous cell carcinoma
(SCC) of the oral floor were eligible for the study. Tumor specimens were investigated by means
of tissue micro arrays (TMAs) and immunohistochemistry for the expression of HIF-1. Correlations
between clinical features and the expression of HIF-1 were evaluated by Kaplan-Meier curves, log-
rank tests and multivariate Cox regression analysis.
Results: HIF-1α was frequently overexpressed in a probably non-hypoxia related fashion. The
expression of HIF-1α was related with a significantly improved 5-year survival rate (p < 0.01) and
a significantly increased disease free period (p = 0.01) independent from nodal status and tumour
size. In primary node negative T1/T2 SCC of the oral floor, absence of HIF-1α expression specified
a subgroup of high-risk patients (p < 0.05).
Conclusion: HIF-1α overexpression is an indicator of favourable prognosis in T1 and T2 SCC of
the oral floor. Node negative patients lacking HIF-1α expression may therefore be considered for
adjuvant radiotherapy.
Background
Numerous molecular-biological and clinico-pathological
studies have increased the knowledge about the hypoxia
inducible regulation system in tumour biology. Protec-
tion against hypoxia in solid tumours is an important step
in tumour development and progression. One system in
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hypoxia protection of tumour cells is represented by the
hypoxia-inducible factor 1 (HIF-1) system which plays a
crucial role in biologic processes under hypoxic condi-
tions, especially in angiogenesis and carcinogenesis. HIF-
1 is a heterodimeric protein consisting of an alpha-and
beta subunit [1], in which the HIF-1α subunit mediates
HIF-1 function as a transcription factor in response to cel-
lular hypoxia. Being stabilized under decreased tissue oxy-
gen concentration, it works as a cellular oxygen-sensing
system, and induces the activation of key regulations sys-
tems through more than 40 proteins, including members
of the glucose transporter (GLUT) and carbonic anhydrase
(CA) family in the respective tumour cells [2]. Alteration
and overexpression of HIF-1α has been detected in a vari-
ety of solid tumours, including breast, lung, ovarian and
oral cancer with varying (diffuse and perinecrotic) stain-
ing patterns [3-7]. The expression of HIF-1α turned out to
be of prognostic relevance in different tumours reviewed
by Semenza [2]. The prognostic relevance of HIF-1α in
tumours derived from squamous epithelium is however
controversial.
Independently of improved operation-and adjuvant ther-
apy strategies, the cure rate of oral squamous carcinoma
has not changed significantly over the last decades. It still
remains at approximately 50% over-all survival [8,9]. Bet-
ter understanding of the biology of squamous cell carci-
noma (SCC) of the oral cavity could identify new
prognostic and predictive factors allowing tailoring of sur-
gical and adjuvant therapy
In view of its important role in various cancers, we evalu-
ated HIF-1α expression and related proteins such as GLUT
1 and CA IX in SCC of the oral cavity, which has not well
been documented. The results were correlated with clin-
ico-pathological features and prognosis. Our results dem-
onstrate that non-hypoxia driven HIF-1α-expression is a
frequent finding in SCC of the oral cavity and is associated
with a favourable prognosis.
Methods
Patients and tumour material
Patients with histologically proven squamous cell carci-
noma of the oral floor treated surgically were eligible for
the study. Surgical treatment included radical tumour
resection of the whole tumour with a free histopathologi-
cal margin of at least 4 mm from the tumour borders.
Selective neck dissection of Level I, II, III and V was per-
formed in case of suspect results in preoperative tumour
staging by computerized tomography or sonography
examination or in case of tumour size over 2 cm. Bilateral
selective neck dissection was performed when the tumour
was extending over the midline (according to the recom-
mendation of Robins et al. 2002)[10]. Radiotherapy was
given when lymph node metastases were detected histo-
logically. The series comprised 85 patients (71 men and
14 women) with a median age of 57 years (range 33–87).
All tumours were classified postsurgically according to the
TNM system (2002) [11]. Patients were clinically evalu-
ated in our routine follow-up.
Immunohistochemistry
For tissue microarray (TMA) construction, two punch
biopsies with a diameter of 0.6 mm were taken from the
centre and the periphery (tumour stromal interface) of
each tumour and transferred into the new acceptor block.
TMA construction was performed by using a special tissue
microarray instrument (Beecher Instruments, New Jersey,
USA), according to standard protocols [12,13].
Immunohistochemistry for HIF-1 alpha, its downstream
genes CAIX and Glut-1, and Ki67 was performed on 4-µm
thick slides from the TMA. After deparaffinization and
rehydration, endogenous peroxidase activity was blocked
for 30 minutes in methanol containing 0.3% hydrogen
peroxide. After antigen retrieval, a cooling-off period of 20
minutes preceded the incubation of the primary antibody
(anti-HIF-1α; 1/500 dilution; BD Transduction Laborato-
ries, Lexington, Kentucky, USA). Thereafter, the catalyzed
signal amplification system (DAKO, Glostrup, Denmark)
was used for HIF-1 alpha staining according to the manu-
facturer's instructions. The antibodies were detected by a
standard avidin-biotin complex method with a bioti-
nylated rabbit anti-mouse antibody (DAKO) and an avi-
din-biotin complex (DAKO), and developed with
diaminobenzidine. Before the slides were mounted, all
sections were counterstained for 45 seconds with hema-
toxylin and dehydrated in alcohol and xylene. Appropri-
ate negative (obtained by omission of the primary
antibody) and positive controls were used throughout.
For CA IX staining, sections were incubated without anti-
gen retrieval with mouse anti-CA IX (MN 75; 1/50 dilu-
tion) for 30 minutes at 20°C and subsequently developed
with an avidin-biotin-peroxidase complex method (Envi-
sion system peroxidase mouse; Dako). All sections were
developed using diaminobenzidine, and subsequently
counterstained with haematoxylin.
For GLUT-1 staining, sections were incubated without
antigen retrieval with a rabbit polyclonal anti-GLUT-1
antibody (clone A 3536; Dako) and subsequently devel-
oped with a standard avidin-biotin-peroxidase complex
method (biotinlyated goat antirabbit antibody; Dako;
streptavidin peroxidase system; Dako) using an auto-
stainer (Autostainer 480-2D; LabVision, Freemont, Cali-
fornia, USA).
For Ki-67 staining (anti Ki-67, Mouse MAb, Immunotech
SA, Marseille, France), sections were incubated withBMC Cancer 2005, 5:84 http://www.biomedcentral.com/1471-2407/5/84
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mouse anti-Ki-67 (MN 75; 1/40 dilution) over night at
4°C and subsequently developed with an avidin-biotin-
peroxidase complex method (Envision system peroxidase
mouse; Dako).
For Cyclin D1 staining (anti cyclin D1, Mouse MAb, Santa
Cruz Biotechnology, Santa Cruz, USA), sections were
incubated with mouse anti-cyclin D1 (1/400 dilution) for
20 minutes at 20°C and subsequently developed with an
avidin-biotin-peroxidase complex method (Envision sys-
tem peroxidase mouse; Dako).
The expression of HIF-1α was determined independently
by two pathologists (PJ.v.D., H.B.). Both pathologists
determined the percentage of positive cell nuclei in each
core. The mean percentage value of the two cores repre-
senting one tumour were used for further evaluation.
Three different cut offs for overexpression were set at 1%,
5% and 10% of positively stained nuclei.
Statistical analysis
TNM-stage, histological differentiation and expression of
HIF-1α were related to the duration of the progression-
free and the overall survival. The measurement of time
started from the date of surgery to the date of histologi-
cally proven recurrent or metastatic carcinoma or disease
related death, respectively. Patients who died from inter-
current diseases were censored at the date of death.
Patients lost to follow-up were censored at the date of the
last examination. Progression-free survival curves and the
overall survival curves were constructed according to Kap-
lan and Meier [14]. The log-rank test was used to assess
differences between groups and the multivariate survival
analysis was performed with Cox regression [15].
Correlations between clinicopathologic features and
expression of HIF-1α were evaluated by chi-square test. A
p-value < 0.05 was considered to be significant.
Results
Clinical and tumour details of the 85 patients with oral
floor squamous cell cancer are shown in Table 1.
HIF-1α expression was confined to the nuclei of neoplas-
tic cells (according to Beasley et al. [4] and Bos et al. [16]).
The expression levels did not differ much for the vast
majority of the cases between the two tumour cores repre-
senting one case, indicating a rather homogeneous expres-
sion throughout the tumours. The difference between the
evaluations of %HIF-1α expressing cells by both patholo-
gists was within the range of 10%.
Detectable levels of HIF-1α (HIF-1α ≥ 1%) were found
within the tumour cells in 63,5% (54/85) of the oral
SCCs. Low levels of nuclear staining (HIF-1α ≥ 1% and <
5%) were found in 11,6 % (9/85) of the tumour specimen
with detectable HIF-1α-expression, high levels of HIF 1-α
expression (≥ 5%) were found in 52,9% (45/85) of the
positive tumour specimens and very high levels (≥10%)
were found in 35,9% (30/85) of the cases. HIF-1α expres-
sion was usually diffuse and tended to be more prominent
towards the centre of tumour fields, sometimes associated
with a better differentiation, indicated by the presence of
keratinized tumour parts. In less than 5% of the cases
necrotic areas were seen, and expression of HIF-1α could
also be detected in perinecrotic vital tumour cells. HIF-1α-
expression could be detected in the tumour stroma in only
5 cases. Cytoplasmatic expression was in 7 of 45 cases, all
associated with nuclear staining levels of HIF-1α ≥ 5 %.
89.5 % (76/85) of the specimens showed membrane
expression of Glut1 and 26% (12/85) of CA IX of neoplas-
tic cells. No correlation could be demonstrated between
HIF-1α, CA IX or Glut I, respectively.
No correlation was found between tumour size, tumour
differentiation, lymph node status and expression of HIF-
1α (≥1%, ≥5%, ≥10%). Also no correlation between the
three expression levels of HIF-1α, cyclin D1 and Ki-67
could be shown in Chi-square test. Kaplan-Meier analysis
of HIF-1α expression ≥1% and ≥10% showed no
significantly association with disease free (p > 0.05) and
overall survival (p > 05).
Kaplan-Meier analysis of carcinomas with low HIF 1-α
expression (HIF-1α ≤ 5%) showed a significantly poorer
disease free (p < 0.01) and overall survival (p < 0.01)
Table 1: Tumour patient cases in this study
Age (mean) 57 years (range 33 – 87 years)
Sex 83.5 % men, 16,5 % women
Follow-up (mean) 51.8 months (range 4 – 154 months)
T stadium 50 T1 tumours and 35 T2 tumours
N stadium 60 lymph node negative-and 25 lymph node positive carcinoma without extracapsular spread
Grading 17 well differentiated tumours (G1)
59 moderately differentiated tumours (G2)
9 weakly differentiated tumours (G3)BMC Cancer 2005, 5:84 http://www.biomedcentral.com/1471-2407/5/84
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(Figs. 1 and 2). No significant association between sur-
vival and the expression of CA IX or Glut-1 were found.
In the subgroup node negative T1/T2 tumours of the oral
floor low HIF-1α expression was also correlated with a
poor overall survival (p < 0.01) (Fig. 3). In multivariate
Cox analysis we compared the overall survival and the dis-
ease free survival according to clinical usual prognostic
factors tumour size and nodal status and also to cyclin D1
and Ki 67 with the HIF-1α expression. Nodal status,
tumour size and HIF-1α expression were identified by
Cox regression as independent predictors of overall sur-
vival (Table 2). Tumour size and HIF-1 expression were
also predictors of tumour free survival in multivariate
regression (Table 3).
Discussion
Postsurgical individual therapy decision making in SCC of
the oral cavity is hampered by the lack of reliable
prognostic markers. Whereas patients with histologically
proven lymph node metastases are subjected to radiother-
apy, this situation is much more complicated in primary
Overall survival of patient with oral squamous cell carcinoma in dependence on HIF-1 expression calculated by the Kaplan- Meier method Figure 1
Overall survival of patient with oral squamous cell carcinoma in dependence on HIF-1 expression calculated by the Kaplan-
Meier method.
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lymph-node negative SCC. Postsurgical radiotherapy in
these patients may often be over-treatment, as only a sub-
group of poor prognosis lymph-node negative carcinomas
would benefit from this type of adjuvant therapy. Never-
theless, at the present state of knowledge no reliable
marker exists that identifies these patients.
In recent years it could be shown that the expression of
HIF-1α might be a potential candidate for the prognostic
assessment for a variety of malignancies. The HIF-1 sys-
tem represents one of the central cellular anti-hypoxia sys-
tems. From a clinical point of view, high levels of HIF 1-α
expression seem to predict a poor prognosis for various
cancers [17-19].
In our study we aimed to evaluate the prognostic value of
HIF 1-α in squamous cell carcinomas of the oral floor
with focus on the clinically important subgroup of node
negative cases. Up to date only a few data exist about the
expression of HIF 1-α in correlation to prognosis in oral
SCC, especially after surgical treatment without adjuvant
radiotherapy. Unexpectedly, we were able to show that
HIF-1α overexpression was related to a significantly
poorer 5-year disease free and overall survival. In the clin-
ically most relevant primary node negative T1/T2
Tumor-free survival of patient with oral squamous cell carcinoma in dependence on HIF-1 expression calculated by the Kaplan- Meier method Figure 2
Tumor-free survival of patient with oral squamous cell carcinoma in dependence on HIF-1 expression calculated by the Kaplan-
Meier method.
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Overall survival of nodal negative patient with oral squamous cell carcinoma in dependence on HIF-1 expression calculated by  the Kaplan-Meier method Figure 3
Overall survival of nodal negative patient with oral squamous cell carcinoma in dependence on HIF-1 expression calculated by 
the Kaplan-Meier method.
Table 2: Multivariate analysis of survival in relation to the HIF-1α expression and other prognostic factors
Prognosticator P valuea RRb Confidence intervalc
Tumor size 0.005 3.4 1.4–7.8
Nodal status 0.003 2.3 1.3–4.2
HIF-1α 0.001 0.2 0.1–0.5
Cyclin D1 0.398 1.3 0.7–2.4
Ki-67 0.602 0.9 0.5–1.5
a The partially nonparametric regression model of Cox (1972) was used to evaluate the predictive power of vatious combinations of 
prognosticators in a multivariate manner.
b RR, relative risk
c 95% confidence interval
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tumours, loss of HIF-1α expression identified a subgroup
of high-risk patients. A correlation with other established
markers could not be defined. We are aware that the use
of tissue microarrays might bias immunohistochemical
results, especially in SCC's. However, it has to be stressed
that the two punches representing one tumour were taken
from the centre and the periphery (tumour stromal inter-
face) as previously described by our group for other
tumour entities [20]. We have not seen major, statistically
relevant differences between the two respective punches.
These results are in line with results published by Beasley
et al. [4]. Using full sections, this group was able to dem-
onstrate a rather homogeneous distribution of HIF-1 pos-
itive cells in SCC's. In detail, no major difference could be
found between perinecrotic regions and areas at the
tumour-stromal interface. We are therefore strongly con-
vinced that our results are not biased by the use of two
tumour punches representing the whole tumour. As we
have pointed out ourselves before [21], the TMA tech-
nique may have limitations for proteins showing focal
expression such as HIF-1α when it is expressed next to
small necrotic areas [22]. Nevertheless, even HIF-1α
immunohistochemistry on TMAs has provided relevant
data in breast cancer [23]. However when there is more
diffuse expression of HIF-1α as in oral SCC in the present
study, the small tumour cores forming the TMA will more
likely be representative.
The literature gives no uniform recommendation for a cut
off point of HIF-1α. The used cut off value of HIF-1α
expression varies in the literature. Beasley et al. [4] used a
cut off value for HIF-1α ≥1% in oral cancer. Other authors
used cut off values for HIF-1α between 1% and 5% (Bos R
et al. [6] : HIF-1α ≥ 5%.; Bos R et al. [16] : HIF-1α ≥1%).
With regard to the variety of the used levels, we choose
three different cut off values for HIF-1α expression ≥1%,
≥5% and ≥10%. The 5% threshold of HIF-1α expression
discriminated in our investigation two different popula-
tions with significant statistical differences in survival
prognosis. In this view we have chosen 5% as the cut off
value for the main statistical analysis in our study. In
regard of the existing literature we also determined the
cytoplasmic HIF-1α staining. However, in accordance to
Beasley et al. [4] a cytoplasmic staining was a rather rare
event and did not influence the statistical results.
In contrast to some adenocarcinomas (e.g. breast cancer
[6]), our results indicate that HIF-1α overexpression is
related to good prognosis.
The frequent diffuse type of HIF-1α overexpression is in
contrast with most adenocarcinomas where usually peri-
necrotic, hypoxia induced HIF-1α expression is seen
[6,24]. In breast cancer, diffuse type of HIF-1α overexpres-
sion is probably non-functional [25]. The diffuse pattern
of HIF-1α staining is not hypoxia related but is due to
alterations in oncogene or tumour suppressor genes
(review Semenza [2]). The frequent diffuse HIF-1α
expression in SCC of the oral cavity is probably also not
hypoxia related. This hypothesis is substantiated by the
lack of CAIX and Glut-1 expression, 2 important down-
stream targets of HIF-1α in the present study. This indi-
cates that the expression of HIF-1α in oral SCC is rather
oncogene/tumour suppressor gene related. In view of the
observed expression of HIF-1α expression in the higher
layers of normal squamous epithelium and the relation to
keratinisation in SCC, HIF-1α may have a physiological
role in differentiation in cases with diffuse expression.
Thereby, HIF-1α expression may be an epiphenomenon
rather than constitute a carcinogenetic event in these
cases.
Only a small minority of SCC revealed necrotic tumour
areas, frequently associated with HIF-1α expression and
expression of CAIX and Glut-1, pointing to a hypoxia
induced event. These cases tended to be of poor prognosis
Table 3: Multivariate analysis of disease free survival in relation to the HIF-1α expression and other prognostic factors
Prognosticator P valuea RRb Confidence intervalc
Tumor size 0.11 2.1 0.8–5.1
Nodal status 0.93 1.0 0.5–2,3
HIF-1α 0.01 0.3 0.1–0.7
Cyclin D1 0.43 1.4 0.6–3,0
Ki-67 0.99 1.0 0.6–1.8
a The partially nonparametric regression model of Cox (1972) was used to evaluate the predictive power of vatious combinations of 
prognosticators in a multivariate manner.
b RR, relative risk
c 95% confidence intervalBMC Cancer 2005, 5:84 http://www.biomedcentral.com/1471-2407/5/84
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Also in adenocarcinomas of the breast, diffuse HIF-1α
expression was associated with a better survival than
hypoxia induced perinecrotic HIF-1α expression [25].
Our results confirm those by Beasley et al. [4] who also
reported a better clinical outcome of HIF-1α overexpress-
ing head&neck SCC, but are at variance with another
study on that reported the opposite [26]. Significant vari-
ations in the application of postsurgical radiotherapy may
however at least in part explain the divergent results.
A small number of cases revealed HIF-1α-expression in
fibroblastic cells. Recently, it could be shown that the stro-
mal expression of CA IX indicated an improved patient
prognosis in invasive breast cancer. The number oral SCC
cases showing stromal HIF-1α expression was too small to
evaluate its clinical significance. In view of the potential
functional role of HIF-1α expression in the stroma of SCC
this deserves to be further studied.
Conclusion
In summary, we were able to show frequent, probably
non-hypoxia related expression of HIF-1-α in oral floor
SCC that is related with improved prognosis. Lymph node
negative patients lacking HIF-1α may be considered for
adjuvant radiotherapy when these results can be con-
firmed in independent studies.
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